Agenus posted on LinkedIn:
“Agenus will present new data from its expanded MSS metastatic colorectal cancer cohort at ESMO GI25.
This poster will feature mature clinical outcomes, including durability of response and overall survival from the Phase 1 study of botensilimab and balstilimab.
Access full details.”
More posts featuring Agenus.